Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Nektar Therapeutics

    NASDAQ: NKTR · Real-Time Price · USD
    8.56
    -0.20 (-2.28%)
    At close: Jun 13, 2025, 3:59 PM
    8.61
    0.53%
    After-hours: Jun 13, 2025, 05:30 PM EDT
    -2.28%
    Bid 8.61
    Market Cap 106.27M
    Revenue (ttm) 87.25M
    Net Income (ttm) -133.04M
    EPS (ttm) -9.45
    PE Ratio (ttm) -0.91
    Forward PE -0.73
    Analyst Buy
    Ask 9.3
    Volume 422,981
    Avg. Volume (20D) 186,660
    Open 8.42
    Previous Close 8.76
    Day's Range 8.22 - 9.13
    52-Week Range 6.45 - 22.80
    Beta 0.56

    About NKTR

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol NKTR
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for NKTR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    2 months ago
    +23.77%
    Nektar Therapeutics shares are trading higher afte... Unlock content with Pro Subscription
    3 months ago
    +9.98%
    Nekar Therapeutics shares are trading higher after Oppenheimer upgraded the stock from Perform to Outperform and announced a price target of $6.
    news image

    4 days ago · seekingalpha.com

    Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC

    Results from Nektar Therapeutics' phase 2b REZOLVE-AD study, using REZPEG for the treatment of patients with atopic dermatitis, are expected in June 2025. The global atopic dermatitis treatment market...

    news image

    1 month ago · zacks.com

    Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down

    NKTR incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year.

    news image

    1 month ago · seekingalpha.com

    Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Transcript

    Nektar Therapeutics (NASDAQ:NKTR ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Corinne Franklin – Investor Relations Howard Robin – President and Chief Executive Offic...

    news image

    1 month ago · zacks.com

    Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates

    Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.18 per share a year ago.

    news image

    1 month ago · zacks.com

    Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know

    Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    news image

    2 months ago · zacks.com

    Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report?

    Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?

    news image

    3 months ago · zacks.com

    Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)

    Nektar Therapeutics (NKTR) came out with quarterly loss of $0.15 per share, missing the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.22 per share a year ago.

    news image

    3 months ago · zacks.com

    Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up

    NKTR fourth-quarter earnings and revenues lag estimates. 2025 is poised to be a catalyst year for rezpeg, with multiple data readouts expected.

    Add to Watchlist